High frequency of primary hyperaldosteronism among hypertensive patients from a primary care area in Sweden

Figures & data

Figure 1.  Flow diagram of patients with increased ARR.

Table I.  Clinical and biochemical variables in patients screened for primary aldosteronism with a raised (>100) and normal (<100) aldosterone/renin ratio.

Variables	Ratio > 100 n = 50 (%)	Ratio < 100 n = 150 (%)	p value
Heredity	25 (50)	90 (60)	0.15
Duration of hypertension (years)	10±8	9±8	0.35
Systolic BP (mmHg)	159±21	154±20	0.15
Diastolic BP(mmHg)	91±11	93±11	0.56
S-Na^+ (mmol/L)	142±2	142±2	0.29
S-K^+ (mmol/L)	3.9±0.3	4.0±0.2	0.16
Creatinine (µmol/L)	72±15	73±14	0.62
Number of hypertensive drugs	1.0±0.6	1.1±0.6	0.66
Beta blockers	19 (38)	63 (42)	0.35
ACE inhibitors	6 (12)	24 (16)	0.53
Diuretics	22 (44)	49 (33)	0.11
Ca channel blockers	17 (34)	21 (14)	0.002
Angiotensin II antagonist	4 (8)	21 (14)	0.24
Alfa 1 blockers	0 (0)	1 (0.6)	>0.99

Data are given as the mean value±SD.

Table II.  Clinical and biochemical variables in patients with a positive and a negative fludrocortisone suppression test.

Variables	Positive fludrocortisone suppression test n = 17 (%)	Negative fludrocortisone suppression test n = 10 (%)	p-value
Heredity (%)	13(76)	4 (40)	0.10
Duration of hypertension (years)	10±8	5±4	0.12
Systolic BP(mmHg)	163±26	158±14	0.96
Diastolic BP(mmHg)	93±11	91±11	0.80
S-K^+ (mmol/L)	3.8±0.4	4.1±0.4	0.02
Creatinine (µmol/L)	72±12	65±8	0.14
Number of hypertensive drugs	1.0±0.7	1.2±0.4	0.45

Data are given as the mean value±SD.